ChartMill assigns a Buy % Consensus number of 86% to ELOX. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-07-11 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-04-06 | Oppenheimer | Reiterate | Outperform |
| 2022-05-23 | Piper Sandler | Maintains | Overweight |
| 2022-05-09 | HC Wainwright & Co. | Maintains | Neutral |
| 2021-12-17 | Oppenheimer | Initiate | Outperform |
| 2021-11-18 | HC Wainwright & Co. | Maintains | Neutral |
| 2021-11-11 | HC Wainwright & Co. | Maintains | Neutral |
| 2021-06-30 | Mizuho | Initiate | Buy |
| 2021-05-27 | B. Riley Securities | Initiate | Buy |
7 analysts have analysed ELOX and the average price target is 61.2 USD. This implies a price increase of 1502.09% is expected in the next year compared to the current price of 3.82.
The consensus rating for ELOXX PHARMACEUTICALS INC (ELOX) is 85.7143 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering ELOXX PHARMACEUTICALS INC (ELOX) is 7.